WXIBF:OTC-WuXi Biologics (Cayman) Inc (USD)

COMMON STOCK | Biotechnology | OTC

Last Closing Price

USD 15.07

Change

-0.24 (-1.57)%

Market Cap

USD 64.87B

Volume

900.00

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

WuXi Biologics (Cayman) Inc., an open-access biologics technology platform company, provides solutions to organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing in the People's Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sales of medicals; vaccine CDMO and related business; and material supplier activities. It has strategic partnerships with Almirall, S.A.; Vir Biotechnology, Inc.; Aravive, Inc.; Tubulis GmbH; Arcus Biosciences, Inc.; AC Immune SA; and AB2 Bio Ltd. The company was incorporated in 2014 and is headquartered in Wuxi, China. WuXi Biologics (Cayman) Inc. is a subsidiary of WuXi Biologics Holdings Limited.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF Novo Nordisk A/S

-1.05 (-1.02%)

USD243.23B 34.25 3.79
CMXHF CSL Limited

-3.84 (-1.67%)

USD104.35B 43.95 29.42
CSLLY CSL Limited

-1.32 (-1.16%)

USD104.08B 43.84 29.42
WXXWY WuXi Biologics (Cayman) Inc

-0.83 (-2.69%)

USD65.34B 155.76 28.65
GNMSF Genmab A/S

+11.27 (+2.57%)

USD28.63B 73.00 8.17
UCBJF UCB SA

N/A

USD22.22B 19.64 14.67
UCBJY UCB SA

-0.78 (-1.37%)

USD21.10B 19.64 14.67
SBHMY Sino Biopharmaceutical Limited

N/A

USD16.22B 10.75 2.15
SBMFF Sino Biopharmaceutical Limited

N/A

USD15.66B 10.39 2.15
GNNSF Genscript Biotech Corporation

N/A

USD8.90B 205.45 N/A

ETFs Containing WXIBF

Symbol Name Weight Mer Price(Change) Market Cap
AIA iShares Trust - iShares A.. 0.00 % 0.50 %

-1.19 (-1.49%)

USD2.72B
SUSM:LSE iShares IV Public Limited.. 0.00 % 0.25 %

-0.06 (-0.66%)

USD2.66B
HMFE:LSE HSBC ETFs Public Limited .. 0.00 % 0.60 %

-23.73 (-0.57%)

USD0.03B
IDFX:LSE iShares Public Limited Co.. 0.00 % 0.74 %

-1.60 (-1.46%)

USD0.63B
IEEM:LSE iShares Public Limited Co.. 0.00 % 0.75 %

-12.13 (-0.34%)

USD3.94B
IFFF:LSE iShares Public Limited Co.. 0.00 % 0.74 %

-27.00 (-0.57%)

USD1.83B
SAEM:LSE iShares MSCI EM IMI ESG S.. 0.00 % 0.18 %

-0.05 (-0.64%)

USD1.71B
SEDM:LSE iShares MSCI EM IMI ESG S.. 0.00 % 0.18 %

+0.04 (+0.56%)

USD0.32B
SEMA:LSE iShares III Public Limite.. 0.00 % 0.68 %

-12.00 (-0.39%)

USD1.23B
HMEM:LSE HSBC ETFs Public Limited .. 0.00 % 0.40 %

-0.10 (-0.74%)

USD1.33B
HMFD:LSE HSBC ETFs Public Limited .. 0.00 % 0.60 %

-0.44 (-0.76%)

USD0.03B
SUES:LSE iShares IV Public Limited.. 0.00 % 0.35 %

-1.00 (-0.16%)

USD2.66B
UC79:LSE UBS ETF SICAV - MSCI Emer.. 0.00 % 0.27 %

-3.25 (-0.28%)

USD1.03B
HMCH:LSE HSBC ETFs Public Limited .. 0.00 % 0.60 %

-6.38 (-0.97%)

USD0.64B
XCS6:LSE Xtrackers - MSCI China UC.. 0.00 % 0.65 %

-0.30 (-1.46%)

USD1.71B
XCX6:LSE Xtrackers - MSCI China UC.. 0.00 % 0.00 %

-13.50 (-0.92%)

USD1.71B
XMME:LSE Xtrackers (IE) Public Lim.. 0.00 % 0.18 %

-0.51 (-0.83%)

USD6.29B
XMMS:LSE Xtrackers (IE) Public Lim.. 0.00 % 0.18 %

-19.00 (-0.42%)

USD6.29B
XX25:LSE Xtrackers - FTSE China 50.. 0.00 % 0.00 %

-22.51 (-0.83%)

USD0.12B
XX2D:LSE Xtrackers - FTSE China 50.. 0.00 % 0.60 %

N/A

USD0.12B
KESG KraneShares Trust - Krane.. 0.00 % 0.59 %

-0.56 (-1.92%)

N/A
EMXF iShares Trust - iShares .. 0.00 % 0.16 %

-0.32 (-0.73%)

N/A
LDEM iShares ESG MSCI EM Leade.. 0.00 % 0.16 %

-0.62 (-1.00%)

N/A
IEMA:LSE iShares III Public Limite.. 0.00 % 0.18 %

-0.33 (-0.78%)

N/A
NTSE Wisdomtree Trust - Wisdom.. 0.00 % 0.32 %

-0.78 (-1.99%)

N/A
HMEF:LSE HSBC ETFs Public Limited .. 0.00 % 0.40 %

-4.81 (-0.51%)

USD1.33B
HMCD:LSE HSBC ETFs Public Limited .. 0.00 % 0.30 %

-0.13 (-1.45%)

USD0.64B
BKF iShares MSCI BRIC ETF 0.00 % 0.70 %

-0.74 (-1.52%)

USD0.16B
CHNA ETF Series Solutions - Lo.. 0.00 % 0.79 %

-0.95 (-2.45%)

USD0.02B
CHB Global X China Biotech In.. 0.00 % 0.67 %

-0.16 (-0.95%)

N/A
CN Xtrackers MSCI All China .. 0.00 % 0.50 %

-0.60 (-1.48%)

USD0.03B
CXSE WisdomTree Trust - Wisdom.. 0.00 % 0.32 %

-0.87 (-1.63%)

USD1.01B
DBEM Xtrackers MSCI Emerging M.. 0.00 % 0.66 %

-0.21 (-0.77%)

USD0.12B
EEMO Invesco S&P Emerging Mark.. 0.00 % 0.31 %

-0.22 (-1.20%)

USD8.23M
FXI iShares Trust - iShares C.. 0.00 % 0.74 %

-0.82 (-2.10%)

USD5.00B
GXC SPDR Index Shares Funds -.. 0.00 % 0.59 %

-2.03 (-1.82%)

USD1.89B
MCHI iShares MSCI China ETF 0.00 % 0.59 %

-1.39 (-2.04%)

USD7.33B
KURE KraneShares MSCI All Chin.. 0.00 % 0.65 %

-0.34 (-0.91%)

USD0.24B
CHNA ETF Series Solutions - Lo.. 0.00 % 0.79 %

-0.95 (-2.45%)

USD0.02B
KMED KraneShares Emerging Mark.. 0.00 % 0.80 %

-0.31 (-0.98%)

USD4.93M
HMAF:LSE HSBC ETFs Public Limited .. 0.00 % 0.45 %

-0.26 (-0.61%)

USD0.64B
EMSG DBX ETF Trust - Xtrackers.. 0.00 % 0.20 %

-0.32 (-0.97%)

USD0.02B
CHIH Global X MSCI China Healt.. 0.00 % 0.65 %

-0.39 (-1.46%)

USD0.02B
CHIL Global X Funds - Global X.. 0.00 % 0.29 %

-0.18 (-0.56%)

USD0.01B
CEA1:LSE iShares VII Public Limite.. 0.00 % 0.00 %

-67.00 (-0.48%)

USD1.64B
CEMA:LSE iShares VII Public Limite.. 0.00 % 0.20 %

-1.85 (-0.96%)

USD1.64B
DBRC:LSE iShares II Public Limited.. 0.00 % 0.74 %

-0.42 (-1.32%)

USD0.21B
EIMI:LSE iShares Core MSCI EM IMI .. 0.00 % 0.18 %

-0.34 (-0.93%)

USD20.26B
EIMU:LSE iShares Core MSCI EM IMI .. 0.00 % 0.18 %

-0.05 (-0.85%)

USD0.81B
EMIM:LSE iShares Public Limited Co.. 0.00 % 0.18 %

-8.50 (-0.32%)

USD17.99B
FXC:LSE iShares Public Limited Co.. 0.00 % 0.00 %

-80.00 (-1.00%)

USD0.63B
HMAD:LSE HSBC ETFs Public Limited .. 0.00 % 0.45 %

-0.65 (-1.13%)

USD0.64B
EDG2:LSE Ishares Iv Plc - Ishares .. 0.00 % 0.18 %

-0.01 (-0.29%)

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 19.89% 65% D 59% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.89% 65% D 57% F
Trailing 12 Months  
Capital Gain 489.70% 93% A 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 489.70% 93% A 93% A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 309.80% 86% B 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 309.80% 86% B 89% B+
Risk Return Profile  
Volatility (Standard Deviation) 358.90% 22% F 17% F
Risk Adjusted Return 86.32% 97% A+ 95% A
Market Capitalization 64.87B 98% A+ 98% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 154.65 14% F 5% F
Price/Book Ratio 20.97 22% F 8% F
Price / Cash Flow Ratio 34.48 9% F 7% F
EV/EBITDA 28.65 29% F 14% F
Management Effectiveness  
Return on Equity 12.01% 86% B 72% C-
Return on Invested Capital 7.86% 59% F 67% D+
Return on Assets 5.42% 92% A- 83% B
Debt to Equity Ratio 8.94% 41% F 67% D+
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.08 40% F 41% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.